Equity Profile

DXCM

DexCom, Inc.

Health CareHealth Care Equipment$29.5B

Jul29Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

DexCom, Inc. is a healthcare company that specializes in continuous glucose monitoring systems for people with diabetes....

Key Metrics to Watch

Continuous Glucose Monitoring Sales

This metric is vital as it directly reflects the demand for DexCom's core products and overall revenue growth.

N/A

Market Share in Diabetes Care

Understanding market share helps gauge DexCom's competitive position and growth potential in the diabetes management sector.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

DXCM Q2-2026 Earnings Preview

Context

Company Snapshot

DexCom, Inc. is a healthcare company that specializes in continuous glucose monitoring systems for people with diabetes. With a market cap of $29 billion, it plays a crucial role in improving diabetes management through innovative technology, which is increasingly important as the prevalence of diabetes rises globally.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+0.22%

Avg Stock Reaction

-0.38%

Last Quarter Recap

In the last quarter, DexCom reported an earnings per share (EPS) of $0.56, beating expectations by nearly 20%. The stock reacted positively, gaining 3.46% the next day.

Management Promises & Guidance

Continued focus on expanding market share in diabetes care.
Commitment to innovation and product development.
Plans to enhance customer support and education.

Expectations

Wall Street Expectations

Investors are cautiously optimistic about DexCom's upcoming earnings report, especially after a strong EPS performance last quarter. However, there are concerns about market competition and pricing pressures.

Bull Case

If DexCom can demonstrate strong sales growth and maintain its market leadership, it could see significant stock appreciation.

Bear Case

On the other hand, if the company fails to meet growth expectations or faces increased competition, the stock could experience downward pressure.

Expectations

Two Questions That Matter

The print will turn on these two things.

What are the sales figures for the new continuous glucose monitoring products?

Sales figures will indicate how well DexCom is capturing market demand and can influence investor confidence.

How is DexCom addressing competitive pressures in the diabetes management market?

Understanding the company's strategy to maintain its market position will be crucial for assessing future growth prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate DexCom's ability to innovate and capture market share, especially with new product launches on the horizon.

Supporting Evidence

DexCom has a history of beating EPS estimates, indicating stronger-than-expected performance.

The options market is pricing a larger move than historical averages, suggesting heightened expectations.

Insider buying activity, although minimal, could signal confidence in the company's future.

Key Risk

If the new product sales exceed expectations, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter, the focus is on how well DexCom can maintain its growth trajectory amidst increasing competition.

Bull Confirmed If

Sales growth of over 15% year-over-year would confirm strong demand and market leadership.

Bear Confirmed If

Sales growth below 5% would raise concerns about market share erosion and competitive pressures.

Pre-Earnings Positioning

Options Market

Implied Move

±14.1%

Historical Avg

±2.1%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±14.1% while DXCM has averaged ±2.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

46.5%

Calls (390K)P/C Ratio: 0.28Puts (105K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If DexCom beats expectations, history suggests the stock could rise by around 2.13% on the following day, confirming strong market demand.

In-Line / Cautious

If results are in line but management expresses caution, the stock may react neutrally, reflecting uncertainty.

Miss

If the company misses expectations, history suggests a potential decline of about 0.65%, indicating market disappointment.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

Senate only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

R-ARJohn BoozmanSen.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the launch and sales performance of new continuous glucose monitoring products.
2Management's commentary on competitive pressures and market strategies.
3Any guidance on future revenue growth and market share targets.
4Insights into customer feedback and satisfaction with current products.
5Discussion of potential partnerships or collaborations in the healthcare space.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

DexCom, Inc. is a healthcare company that specializes in continuous glucose monitoring systems for people with diabetes....

Key Metrics to Watch

Continuous Glucose Monitoring Sales

This metric is vital as it directly reflects the demand for DexCom's core products and overall revenue growth.

N/A

Market Share in Diabetes Care

Understanding market share helps gauge DexCom's competitive position and growth potential in the diabetes management sector.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

DXCM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+0.22%

Avg Stock Reaction

-0.38%

Last Quarter Recap

In the last quarter, DexCom reported an earnings per share (EPS) of $0.56, beating expectations by nearly 20%. The stock reacted positively, gaining 3.46% the next day.

Management Promises & Guidance

Continued focus on expanding market share in diabetes care.
Commitment to innovation and product development.
Plans to enhance customer support and education.

Expectations

Wall Street Expectations

Bull Case

If DexCom can demonstrate strong sales growth and maintain its market leadership, it could see significant stock appreciation.

Bear Case

On the other hand, if the company fails to meet growth expectations or faces increased competition, the stock could experience downward pressure.

Expectations

Two Questions That Matter

The print will turn on these two things.

What are the sales figures for the new continuous glucose monitoring products?

Sales figures will indicate how well DexCom is capturing market demand and can influence investor confidence.

How is DexCom addressing competitive pressures in the diabetes management market?

Understanding the company's strategy to maintain its market position will be crucial for assessing future growth prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate DexCom's ability to innovate and capture market share, especially with new product launches on the horizon.

Supporting Evidence

DexCom has a history of beating EPS estimates, indicating stronger-than-expected performance.

The options market is pricing a larger move than historical averages, suggesting heightened expectations.

Insider buying activity, although minimal, could signal confidence in the company's future.

Key Risk

If the new product sales exceed expectations, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter, the focus is on how well DexCom can maintain its growth trajectory amidst increasing competition.

Bull Confirmed If

Sales growth of over 15% year-over-year would confirm strong demand and market leadership.

Bear Confirmed If

Sales growth below 5% would raise concerns about market share erosion and competitive pressures.

Pre-Earnings Positioning

Options Market

Implied Move

±14.1%

Historical Avg

±2.1%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±14.1% while DXCM has averaged ±2.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

46.5%

Calls (390K)P/C Ratio: 0.28Puts (105K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If DexCom beats expectations, history suggests the stock could rise by around 2.13% on the following day, confirming strong market demand.

In-Line / Cautious

If results are in line but management expresses caution, the stock may react neutrally, reflecting uncertainty.

Miss

If the company misses expectations, history suggests a potential decline of about 0.65%, indicating market disappointment.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

Senate only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

R-ARJohn BoozmanSen.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the launch and sales performance of new continuous glucose monitoring products.
2Management's commentary on competitive pressures and market strategies.
3Any guidance on future revenue growth and market share targets.
4Insights into customer feedback and satisfaction with current products.
5Discussion of potential partnerships or collaborations in the healthcare space.